Brian J. Lannutti
- Genetics top 0.2%
- Chronic Lymphocytic Leukemia Research 48
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 19
- Hematology top 1%
- Platelet Disorders and Treatments 8
- Chronic Myeloid Leukemia Treatments 8
- Multiple Myeloma Research and Treatments 7
- Immunology top 2%
- Oncology top 5%
- CAR-T cell therapy research 6
-
- PI3K/AKT/mTOR signaling in cancer 26
-
- Advanced Breast Cancer Therapies 8
Brian J. Lannutti
74 papers receiving 3.9k citations
Hit Papers
Peers
Comparison fields: 5 of 93
- Genetics 2.6k
- Pathology and Forensic Medicine 1.7k
- Hematology 991
- Immunology 1.0k
- Oncology 831
Countries citing papers authored by Brian J. Lannutti
This map shows the geographic impact of Brian J. Lannutti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian J. Lannutti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian J. Lannutti more than expected).
Fields of papers citing papers by Brian J. Lannutti
This network shows the impact of papers produced by Brian J. Lannutti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian J. Lannutti. The network helps show where Brian J. Lannutti may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Brian J. Lannutti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 25 | |
| 2 | 2017 | 7 | |
| 3 | 2017 | 4 | |
| 4 | 2016 | 121 | |
| 5 | 2016 | 1 | |
| 6 | 2013 | 36 | |
| 7 | 2013 | 75 | |
| 8 | 2013 | 59 | |
| 9 | 2013 | 30 | |
| 10 | 2012 | 2 | |
| 11 | 2012 | 69 | |
| 12 | The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiabreakdown → | 2011 | 442 |
| 13 | 2010 | 156 | |
| 14 | 2007 | 5 | |
| 15 | 2006 | 38 | |
| 16 | 2005 | 22 | |
| 17 | 2003 | 38 | |
| 18 | 2001 | 17 | |
| 19 | 1999 | 31 | |
| 20 | 1998 | 24 |
About Brian J. Lannutti
Brian J. Lannutti is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 75 papers that have together received 4.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (48 papers), PI3K/AKT/mTOR signaling in cancer (26 papers), Lymphoma Diagnosis and Treatment (19 papers), Advanced Breast Cancer Therapies (8 papers), Platelet Disorders and Treatments (8 papers), Chronic Myeloid Leukemia Treatments (8 papers), Multiple Myeloma Research and Treatments (7 papers) and CAR-T cell therapy research (6 papers). The work is most often cited by research in Genetics (2.6k citations), Pathology and Forensic Medicine (1.7k citations) and Hematology (991 citations). Brian J. Lannutti has collaborated with scholars based in United States, Italy and Denmark. Frequent co-authors include Neill A. Giese, Sarah Meadows, John C. Byrd, Roger G. Ulrich, Langdon L. Miller, Kamal D. Puri, Amy J. Johnson, Albert S. Yu, Sarah E.M. Herman and Adam Kashishian. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.